These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 24557340)

  • 1. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
    BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
    Wang D; Feng J; Xu B
    Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
    [No Abstract]   [Full Text] [Related]  

  • 5. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
    Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
    Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials.
    Guan X; Ma F; Fan Y; Zhu W; Hong R; Xu B
    Anticancer Drugs; 2015 Sep; 26(8):894-901. PubMed ID: 26086398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
    Wu K; Yang Q; Liu Y; Wu A; Yang Z
    World J Surg Oncol; 2014 Apr; 12():95. PubMed ID: 24731479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
    Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
    Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer.
    Feng W; He Y; Xu J; Zhang H; Si Y; Xu J; Li S
    Anticancer Drugs; 2022 Jan; 33(1):e52-e60. PubMed ID: 34371505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
    J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    Vidra R; Nemes A; Vidrean A; Pintea S; Tintari S; Deac A; Ciuleanu T
    Exp Ther Med; 2022 Jan; 23(1):91. PubMed ID: 34934456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
    Agrawal LS; Mayer IA
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Mao Y; Qu Q; Zhang Y; Liu J; Chen X; Shen K
    PLoS One; 2014; 9(12):e115103. PubMed ID: 25501357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials.
    Wang LY; Xie H; Zhou H; Yao WX; Zhao X; Wang Y
    Saudi Med J; 2017 Jan; 38(1):18-23. PubMed ID: 28042625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
    Petrelli F; Barni S; Bregni G; de Braud F; Di Cosimo S
    Breast Cancer Res Treat; 2016 Dec; 160(3):425-437. PubMed ID: 27770282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer.
    Zhang G; Xie W; Liu Z; Lin C; Piao Y; Xu L; Guo F; Xie X
    Tumori; 2014; 100(2):136-42. PubMed ID: 24852856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.